Krsnaa Diagnostics Board Approves Q2 & H1 FY26 Results; Reports Growth Amidst Tax Appeal
Krsnaa Diagnostics approved Q2 and H1 FY26 standalone and consolidated financial results, reporting revenue and profit growth. Company appeals ₹51.39 crore Income Tax demand, expecting no material impact.
The announcement includes the approval of significant financial results showing positive growth, which is a key indicator for investors. The ongoing tax dispute, while a notable item, is not presented as an immediate material risk by the management or auditors, thus moderating the overall impact from high to medium given the positive core business performance.
The company reported consistent growth in both standalone and consolidated revenue and profit for the quarter and half year ended September 30, 2025. While there is an ongoing Income Tax demand of ₹51.39 crore, the management believes it is not tenable and will not have a material impact, a view not contradicted by the auditors.
Krsnaa Diagnostics Limited's Board of Directors met on November 7, 2025, and approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. * Standalone Financial Highlights (Quarter ended September 30, 2025 vs. September 30, 2024): * Revenue from operations increased to ₹182.88 crore from ₹178.72 crore. * Profit for the period rose to ₹23.24 crore from ₹21.97 crore. * Basic Earnings Per Share (EPS) increased to ₹7.12 from ₹6.80. * Standalone Financial Highlights (Half year ended September 30, 2025 vs. September 30, 2024): * Revenue from operations increased to ₹358.50 crore from ₹341.89 crore. * Profit for the period rose to ₹42.80 crore from ₹40.15 crore. * Basic EPS increased to ₹13.22 from ₹12.43. * Consolidated Financial Highlights (Quarter ended September 30, 2025 vs. September 30, 2024): * Revenue from operations increased to ₹205.99 crore from ₹186.34 crore. * Profit for the period rose to ₹23.95 crore from ₹19.60 crore. * Basic EPS increased to ₹7.38 from ₹6.07. * Consolidated Financial Highlights (Half year ended September 30, 2025 vs. September 30, 2024): * Revenue from operations increased to ₹398.97 crore from ₹356.57 crore. * Profit for the period rose to ₹44.47 crore from ₹37.52 crore. * Basic EPS increased to ₹13.73 from ₹11.62. * The company is engaged in ongoing assessment proceedings with Income Tax Authorities related to search operations, resulting in a demand order of ₹51.39 crore (₹513.86 million) for assessment years 2017-18, 2020-21, 2021-22, 2022-23, and 2023-24. Krsnaa Diagnostics has filed appeals against these orders and has paid ₹3.93 crore (₹39.27 million) under protest for AY 22-23, while also requesting to adjust ₹6.35 crore (₹63.50 million) from tax refunds for AY 2024-25 against amounts to be paid under protest for other AYs. The management, based on expert opinion, believes these demand orders are not tenable and will not have a material impact on the company’s financial position or performance for the period ended September 30, 2025. The independent auditor's review report was not modified in respect of this matter.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.